> top > docs > PubMed:32473596 > annotations

PubMed:32473596 JSONTXT

Annnotations TAB JSON ListView MergeView

LitCovid-OGER-BB

Id Subject Object Predicate Lexical cue
T1 0-22 CHEBI:52217 denotes Pharmacological Agents
T2 0-22 CHEBI:52217 denotes Pharmacological Agents
T3 33-52 GO:0007596 denotes Thromboinflammation
T4 56-64 SP_7 denotes COVID-19
T5 111-122 NCBITaxon:11118 denotes Coronavirus
T6 137-145 SP_7 denotes COVID-19
T7 185-190 NCBITaxon:10239 denotes viral
T8 213-260 SP_7 denotes severe acute respiratory syndrome coronavirus 2
T9 226-237 UBERON:0001004 denotes respiratory
T10 262-272 SP_7 denotes SARS-CoV-2
T11 305-315 GO:0007596 denotes thrombotic
T12 353-361 SP_7 denotes COVID-19
T13 436-444 SP_7 denotes COVID-19
T14 456-466 GO:0007596 denotes thrombotic
T15 506-514 SP_7 denotes COVID-19
T16 515-525 GO:0007596 denotes Thrombosis
T17 601-615 GO:0007596 denotes antithrombotic
T18 601-622 CHEBI:67079 denotes antithrombotic agents
T19 601-622 CHEBI:67079 denotes antithrombotic agents
T20 635-642 CHEBI:24505 denotes heparin
T21 635-642 CHEBI:24505 denotes heparin
T22 701-715 CHEBI:67079 denotes antithrombotic
T23 701-715 CHEBI:67079 denotes antithrombotic
T24 716-721 CHEBI:23888 denotes drugs
T25 716-721 CHEBI:23888 denotes drugs
T26 750-760 GO:0007596 denotes thrombosis
T27 803-817 GO:0007596 denotes antithrombotic
T28 1061-1069 SP_7 denotes COVID-19
T29 1114-1130 CHEBI:50846 denotes immunomodulators
T30 1114-1130 CHEBI:50846 denotes immunomodulators
T31 1146-1160 GO:0007596 denotes antithrombotic
T32 1387-1397 GO:0007596 denotes thrombosis
T33 1401-1409 SP_7 denotes COVID-19

Inflammaging

Id Subject Object Predicate Lexical cue
T1 0-65 Sentence denotes Pharmacological Agents Targeting Thromboinflammation in COVID-19:
T2 66-110 Sentence denotes Review and Implications for Future Research.
T3 111-274 Sentence denotes Coronavirus disease 2019 (COVID-19), currently a worldwide pandemic, is a viral illness caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
T4 275-475 Sentence denotes The suspected contribution of thrombotic events to morbidity and mortality in COVID-19 patients has prompted a search for novel potential options for preventing COVID-19-associated thrombotic disease.
T5 476-761 Sentence denotes In this article by the Global COVID-19 Thrombosis Collaborative Group, we describe novel dosing approaches for commonly used antithrombotic agents (especially heparin-based regimens) and the potential use of less widely used antithrombotic drugs in the absence of confirmed thrombosis.
T6 762-926 Sentence denotes Although these therapies may have direct antithrombotic effects, other mechanisms of action, including anti-inflammatory or antiviral effects, have been postulated.
T7 927-1070 Sentence denotes Based on survey results from this group of authors, we suggest research priorities for specific agents and subgroups of patients with COVID-19.
T8 1071-1172 Sentence denotes Further, we review other agents, including immunomodulators, that may have antithrombotic properties.
T9 1173-1410 Sentence denotes It is our hope that the present document will encourage and stimulate future prospective studies and randomized trials to study the safety, efficacy, and optimal use of these agents for prevention or management of thrombosis in COVID-19.
T1 0-65 Sentence denotes Pharmacological Agents Targeting Thromboinflammation in COVID-19:
T2 66-110 Sentence denotes Review and Implications for Future Research.
T3 111-274 Sentence denotes Coronavirus disease 2019 (COVID-19), currently a worldwide pandemic, is a viral illness caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
T4 275-475 Sentence denotes The suspected contribution of thrombotic events to morbidity and mortality in COVID-19 patients has prompted a search for novel potential options for preventing COVID-19-associated thrombotic disease.
T5 476-761 Sentence denotes In this article by the Global COVID-19 Thrombosis Collaborative Group, we describe novel dosing approaches for commonly used antithrombotic agents (especially heparin-based regimens) and the potential use of less widely used antithrombotic drugs in the absence of confirmed thrombosis.
T6 762-926 Sentence denotes Although these therapies may have direct antithrombotic effects, other mechanisms of action, including anti-inflammatory or antiviral effects, have been postulated.
T7 927-1070 Sentence denotes Based on survey results from this group of authors, we suggest research priorities for specific agents and subgroups of patients with COVID-19.
T8 1071-1172 Sentence denotes Further, we review other agents, including immunomodulators, that may have antithrombotic properties.
T9 1173-1410 Sentence denotes It is our hope that the present document will encourage and stimulate future prospective studies and randomized trials to study the safety, efficacy, and optimal use of these agents for prevention or management of thrombosis in COVID-19.

LitCovid-PD-FMA-UBERON

Id Subject Object Predicate Lexical cue fma_id
T1 635-642 Body_part denotes heparin http://purl.org/sig/ont/fma/fma82839

LitCovid-PD-MONDO

Id Subject Object Predicate Lexical cue mondo_id
T1 56-64 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T2 111-135 Disease denotes Coronavirus disease 2019 http://purl.obolibrary.org/obo/MONDO_0100096
T3 137-145 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T4 213-260 Disease denotes severe acute respiratory syndrome coronavirus 2 http://purl.obolibrary.org/obo/MONDO_0100096
T5 213-246 Disease denotes severe acute respiratory syndrome http://purl.obolibrary.org/obo/MONDO_0005091
T6 262-270 Disease denotes SARS-CoV http://purl.obolibrary.org/obo/MONDO_0005091
T7 353-361 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T8 436-444 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T9 456-474 Disease denotes thrombotic disease http://purl.obolibrary.org/obo/MONDO_0000831
T10 506-514 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T11 515-525 Disease denotes Thrombosis http://purl.obolibrary.org/obo/MONDO_0000831
T12 750-760 Disease denotes thrombosis http://purl.obolibrary.org/obo/MONDO_0000831
T13 1061-1069 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T14 1387-1397 Disease denotes thrombosis http://purl.obolibrary.org/obo/MONDO_0000831
T15 1401-1409 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096

LitCovid-PD-CLO

Id Subject Object Predicate Lexical cue
T1 158-159 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T2 183-184 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T3 371-374 http://purl.obolibrary.org/obo/CLO_0051582 denotes has
T4 384-385 http://purl.obolibrary.org/obo/CLO_0001020 denotes a

LitCovid-PD-CHEBI

Id Subject Object Predicate Lexical cue chebi_id
T1 635-642 Chemical denotes heparin http://purl.obolibrary.org/obo/CHEBI_28304
T2 716-721 Chemical denotes drugs http://purl.obolibrary.org/obo/CHEBI_23888
T3 886-895 Chemical denotes antiviral http://purl.obolibrary.org/obo/CHEBI_22587
T4 961-966 Chemical denotes group http://purl.obolibrary.org/obo/CHEBI_24433
T5 1114-1130 Chemical denotes immunomodulators http://purl.obolibrary.org/obo/CHEBI_50846

LitCovid-sentences

Id Subject Object Predicate Lexical cue
T1 0-65 Sentence denotes Pharmacological Agents Targeting Thromboinflammation in COVID-19:
T2 66-110 Sentence denotes Review and Implications for Future Research.
T3 111-274 Sentence denotes Coronavirus disease 2019 (COVID-19), currently a worldwide pandemic, is a viral illness caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
T4 275-475 Sentence denotes The suspected contribution of thrombotic events to morbidity and mortality in COVID-19 patients has prompted a search for novel potential options for preventing COVID-19-associated thrombotic disease.
T5 476-761 Sentence denotes In this article by the Global COVID-19 Thrombosis Collaborative Group, we describe novel dosing approaches for commonly used antithrombotic agents (especially heparin-based regimens) and the potential use of less widely used antithrombotic drugs in the absence of confirmed thrombosis.
T6 762-926 Sentence denotes Although these therapies may have direct antithrombotic effects, other mechanisms of action, including anti-inflammatory or antiviral effects, have been postulated.
T7 927-1070 Sentence denotes Based on survey results from this group of authors, we suggest research priorities for specific agents and subgroups of patients with COVID-19.
T8 1071-1172 Sentence denotes Further, we review other agents, including immunomodulators, that may have antithrombotic properties.
T9 1173-1410 Sentence denotes It is our hope that the present document will encourage and stimulate future prospective studies and randomized trials to study the safety, efficacy, and optimal use of these agents for prevention or management of thrombosis in COVID-19.

LitCovid-PubTator

Id Subject Object Predicate Lexical cue tao:has_database_id
2 33-52 Disease denotes Thromboinflammation
3 56-64 Disease denotes COVID-19 MESH:C000657245
23 111-135 Disease denotes Coronavirus disease 2019 MESH:C000657245
24 137-145 Disease denotes COVID-19 MESH:C000657245
25 185-198 Disease denotes viral illness
26 213-260 Species denotes severe acute respiratory syndrome coronavirus 2 Tax:2697049
27 262-272 Species denotes SARS-CoV-2 Tax:2697049
28 305-315 Disease denotes thrombotic MESH:D013927
29 340-349 Disease denotes mortality MESH:D003643
30 353-361 Disease denotes COVID-19 MESH:C000657245
31 362-370 Species denotes patients Tax:9606
32 436-444 Disease denotes COVID-19 MESH:C000657245
33 456-474 Disease denotes thrombotic disease MESH:D013927
34 506-514 Disease denotes COVID-19 MESH:C000657245
35 515-525 Disease denotes Thrombosis MESH:D013927
36 635-642 Chemical denotes heparin MESH:D006493
37 750-760 Disease denotes thrombosis MESH:D013927
38 1047-1055 Species denotes patients Tax:9606
39 1061-1069 Disease denotes COVID-19 MESH:C000657245
40 1387-1397 Disease denotes thrombosis MESH:D013927
41 1401-1409 Disease denotes COVID-19 MESH:C000657245